Center Hospitalier de Bastia is Live on SOPHiA GENETICS

SOPHiA DDM Platform will bring next-generation sequencing in-house and help further to research hematological malignancies

BOSTON and ROLLE, Swiss, July 7, 2023 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that the Center Hospitalier de Bastia is active on the SOPHiA DDM platform. The Center Hospitalier de Bastia, a general hospital located in the city of Bastia on the French island of Corsica, is using the SOPHiA DDM platform to introduce in-house next-generation sequencing (NGS), which will support clinical oncology research and facilitate insights on hematological malignancies.

Hematologic cancers such as leukemia, lymphoma, and myeloma begin in cells of the immune system or in blood-forming tissue, such as bone marrow.[1] These types of cancer, also called blood cancers, are the fourth most common type of cancer in the developed world[2] and can move fast.

The SOPHiA DDM platform is a cloud-based platform that uses Artificial Intelligence (AI) with patented technologies to synthesize next-generation sequencing (NGS) data; this is critical when classifying disease-associated mutations. The SOPHiA DDM platform will allow the Center Hospitalier de Bastia to develop internal expertise, enhance its molecular testing capabilities and help accelerate research into hematological malignancies and potentially other types of cancer.

Using the SOPHiA DDM platform, the Center Hospitalier de Bastia will be able to synchronize its testing and reporting capabilities between the four units of the Pole Technique et Medico-Technique center and the public health department; this will support accelerated analysis and better equip researchers as they work to practice data-driven medicine.

“Next-generation sequencing has become the gold standard in genomic testing, especially for fast-moving and sometimes complex cancers like hematologic malignancies,” said Kevin Puylaert, vice president of business development and marketing, GENETIC SOPHIA. “Using the SOPHiA DDM platform, the Center Hospitalier de Bastia is enhancing its research capabilities and connecting with world-class institutions globally, making precision medicine a reality in Corsica.”

For more information about SOPHiA GENETICS, visit SOPHiAGENETICS.COM or connect atChirping,LinkedIn, Facebook and Instagram.

About SOPHIA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life science research. He is the creator of the SOPHiA DDM Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal datasets and different diagnostic modalities. The SOPHiA DDM platform and related solutions, products and services are currently used by a large network of hospitals, laboratories and biopharmaceutical institutions globally. For more information, visit SOPHiAGENETICS.COM or log in atChirping,LinkedIn, Facebook and Instagram.Where others see the data, we see the answers.

SOPHiA GENETICS products are for research use only and not for use in diagnostic procedures unless otherwise noted. The information in this news release pertains to products that may or may not be available in different countries and, if applicable, may or may not have received approval or marketing authorization from a governmental regulatory body for different directions for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future operating results and financial position, business strategy, products and technology, and management’s plans and objectives for operations future, are forward-looking statements. Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by the forward-looking statements due to various factors, including those described in our filings with the US Securities and Exchange Commission. There can be no assurance that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of today’s date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statements are based, unless required by applicable law. No representations or warranties (express or implied) are made as to the accuracy of any such forward-looking statements.

¹ https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hematologic-cancer
² https://gco.iarc.fr/today/fact-sheets-cancers accessible at May 19, 2021.

SOURCE SOPHIA GENETIC